Perspective Therapeutics (CATX) investor relations material

Strategic positioning and clinical pipeline

• Four clinical programs are advancing, with VMT-α-NET potentially entering a registration trial within a year and three other assets in development, including recent nomination of PSV594.

• Over 100 patients have been dosed across programs, demonstrating robust in-house manufacturing and supply chain capabilities, with a new Chicago facility expected online within a year.

• Cash reserves of $271 million provide runway into late 2027, supporting ongoing and future trials.

• IP protection and a vertically integrated model differentiate the company in the targeted alpha therapy space.

Key clinical data and milestones

• VMT-α-NET cohort 2 shows a 43% overall response rate (50% in SSTR2-positive patients), significantly higher than Lutathera’s 13% label response rate.

• Safety profile for VMT-α-NET is favorable, with minimal kidney toxicity and no grade 4/5 adverse events.

• Cohort 3 (higher dose) and cohort 4 (front-loaded dosing) are underway, with data expected later in the year.

• Upcoming milestones include pivotal trial design for VMT-α-NET, cohort data readouts, and facility progress.

Pipeline updates and differentiation

• VMT-01 is being tested as a single agent and in combination with nivolumab, with further data expected later in the year; no major updates anticipated at ASCO.

• PSV359 (FAP program) targets a broad range of solid tumors, with efficacy data anticipated by year-end.

• PSV594, a newly nominated program, leverages proprietary theranostic and chelator technology for targeted delivery and safety.